Eromona Whiskey

1.4k total citations
57 papers, 896 citations indexed

About

Eromona Whiskey is a scholar working on Psychiatry and Mental health, Genetics and Clinical Psychology. According to data from OpenAlex, Eromona Whiskey has authored 57 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Psychiatry and Mental health, 14 papers in Genetics and 13 papers in Clinical Psychology. Recurrent topics in Eromona Whiskey's work include Schizophrenia research and treatment (47 papers), Blood disorders and treatments (14 papers) and Electroconvulsive Therapy Studies (11 papers). Eromona Whiskey is often cited by papers focused on Schizophrenia research and treatment (47 papers), Blood disorders and treatments (14 papers) and Electroconvulsive Therapy Studies (11 papers). Eromona Whiskey collaborates with scholars based in United Kingdom, United States and Israel. Eromona Whiskey's co-authors include David Taylor, Sukhwinder S. Shergill, James H. MacCabe, Ursula Werneke, Olubanké Dzahini, Ebenezer Oloyede, Fiona Gaughran, Aleksandar Mijović, Shubhra Mace and Siobhan Gee and has published in prestigious journals such as SHILAP Revista de lepidopterología, The British Journal of Psychiatry and Schizophrenia Bulletin.

In The Last Decade

Eromona Whiskey

50 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eromona Whiskey United Kingdom 18 633 201 127 125 111 57 896
Giorgia Giussani Italy 21 872 1.4× 77 0.4× 53 0.4× 47 0.4× 6 0.1× 47 1.2k
Ping Shao China 13 300 0.5× 30 0.1× 34 0.3× 19 0.2× 40 0.4× 28 844
Lara McCartney Australia 5 402 0.6× 42 0.2× 76 0.6× 102 0.8× 48 0.4× 5 495
Jonathan Thomas United States 10 551 0.9× 41 0.2× 140 1.1× 209 1.7× 26 0.2× 25 820
Salvatore De Fazio Italy 14 311 0.5× 36 0.2× 27 0.2× 12 0.1× 12 0.1× 31 693
S A Volpicelli United States 8 447 0.7× 14 0.1× 34 0.3× 25 0.2× 90 0.8× 8 790
Ling Bai China 14 157 0.2× 80 0.4× 71 0.6× 12 0.1× 55 0.5× 57 751
Chathurie Suraweera Sri Lanka 9 308 0.5× 31 0.2× 76 0.6× 20 0.2× 53 0.5× 26 581
Graeme Archer United Kingdom 9 183 0.3× 26 0.1× 69 0.5× 50 0.4× 26 0.2× 15 488
Victoria Burtea Romania 11 194 0.3× 22 0.1× 45 0.4× 22 0.2× 18 0.2× 25 478

Countries citing papers authored by Eromona Whiskey

Since Specialization
Citations

This map shows the geographic impact of Eromona Whiskey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eromona Whiskey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eromona Whiskey more than expected).

Fields of papers citing papers by Eromona Whiskey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eromona Whiskey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eromona Whiskey. The network helps show where Eromona Whiskey may publish in the future.

Co-authorship network of co-authors of Eromona Whiskey

This figure shows the co-authorship network connecting the top 25 collaborators of Eromona Whiskey. A scholar is included among the top collaborators of Eromona Whiskey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eromona Whiskey. Eromona Whiskey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nair, Sandhya K., Sukhwinder S. Shergill, & Eromona Whiskey. (2025). Xanomeline-trospium: defining its place among the current antipsychotic landscape. Acta Neuropsychiatrica. 37. e81–e81.
2.
Shergill, Sukhwinder S., et al.. (2024). Overcoming Obstacles to Clozapine Treatment. Journal of Clinical Psychopharmacology. 44(2). 182–185.
3.
Whiskey, Eromona, et al.. (2024). Developing the New Kent Complex Psychosis Service (KCPS): Reducing the Limitations Imposed by Treatment-Resistant Psychosis. BJPsych Open. 10(S1). S179–S180. 1 indexed citations
4.
Oloyede, Ebenezer, et al.. (2023). The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia. BMC Psychiatry. 23(1). 413–413. 6 indexed citations
5.
Taylor, David, et al.. (2022). Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. SHILAP Revista de lepidopterología. 8(1). 21–21. 30 indexed citations
6.
Oloyede, Ebenezer, Eromona Whiskey, Cecilia Casetta, et al.. (2022). Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. The Lancet Psychiatry. 9(8). 636–644. 25 indexed citations
7.
Oloyede, Ebenezer, Olubanké Dzahini, Aleksandar Mijović, et al.. (2021). Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals. BMC Psychiatry. 21(1). 502–502. 15 indexed citations
8.
Oloyede, Ebenezer, Bárbara Arroyo, Olubanké Dzahini, et al.. (2021). Evaluation of the effectiveness and acceptability of the long-acting oral antipsychotic penfluridol: Illustrative case series. Journal of Psychopharmacology. 36(2). 223–231. 5 indexed citations
9.
Fox, T, et al.. (2020). Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation. SHILAP Revista de lepidopterología. 10. 3627464831–3627464831. 3 indexed citations
10.
Patel, Rishi, Alice Moore, Susan Piper, et al.. (2019). Clozapine and cardiotoxicity – A guide for psychiatrists written by cardiologists. Psychiatry Research. 282. 112491–112491. 30 indexed citations
11.
Sweeney, Mark, Eromona Whiskey, Rishi Patel, et al.. (2019). Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia. BJPsych Advances. 26(1). 26–40. 7 indexed citations
12.
Oloyede, Ebenezer, Olubanké Dzahini, Eromona Whiskey, & David Taylor. (2019). Clozapine and Norclozapine Plasma Levels in Patients Switched Between Different Liquid Formulations. Therapeutic Drug Monitoring. 42(3). 491–496. 9 indexed citations
13.
Krivoy, Amir, Dan W. Joyce, Derek K. Tracy, et al.. (2019). Real-World Outcomes in the Management of Refractory Psychosis. The Journal of Clinical Psychiatry. 80(5). 6 indexed citations
14.
Whiskey, Eromona, et al.. (2018). Clozapine, HIV and neutropenia: a case report. Therapeutic Advances in Psychopharmacology. 8(12). 365–369. 4 indexed citations
15.
Lally, John, Eromona Whiskey, David Taylor, et al.. (2017). Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Psychopharmacology. 37(4). 441–446. 24 indexed citations
16.
Meyer, Nicholas, Siobhan Gee, Eromona Whiskey, et al.. (2015). Optimizing Outcomes in Clozapine Rechallenge Following Neutropenia. The Journal of Clinical Psychiatry. 76(11). e1410–e1416. 33 indexed citations
17.
Whiskey, Eromona & David Taylor. (2013). A review of the adverse effects and safety of noradrenergic antidepressants. Journal of Psychopharmacology. 27(8). 732–739. 50 indexed citations
18.
Sparshatt, Anna, Eromona Whiskey, & David Taylor. (2008). Valproate as prophylaxis for clozapine-induced seizures: survey of practice. Psychiatric Bulletin. 32(7). 262–265. 5 indexed citations
19.
Whiskey, Eromona & David Taylor. (2007). Restarting Clozapine after Neutropenia. CNS Drugs. 21(1). 25–35. 59 indexed citations
20.
Whiskey, Eromona & David Taylor. (2004). Generic clozapine: opportunity or threat?. Pharmaceutical journal/˜The œpharmaceutical journal. 273. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giorgia Giussani Breakdown of academic impact, for papers by Ping Shao Breakdown of academic impact, for papers by Lara McCartney Breakdown of academic impact, for papers by Jonathan Thomas Breakdown of academic impact, for papers by Salvatore De Fazio Breakdown of academic impact, for papers by S A Volpicelli Breakdown of academic impact, for papers by Ling Bai Breakdown of academic impact, for papers by Chathurie Suraweera Breakdown of academic impact, for papers by Graeme Archer Breakdown of academic impact, for papers by Victoria Burtea
Rankless by CCL
2026